Kilroy Realty Corp
Slēgts
SektorsNekustamais īpašums
36.91 -0.51
Pārskats
Akcijas cenas izmaiņa
24h
Min
36.5
Max
37.55
Ienākumi | -295M -19M |
|---|---|
Pārdošana | -2.2M 270M |
P/E Sektora vidējais | 20.219 50.069 |
EPS | 0.16 |
Dividenžu ienesīgums | 5.87 |
Peļņas marža | -7.135 |
Darbinieki | 241 |
EBITDA | -65M 118M |
Rekomendācijas | Neitrāls |
|---|---|
Prognoze 12 mēnešiem | +2.38% upside |
Dividenžu ienesīgums Sektora vidējais | 5.87% 6.28% |
|---|---|
Nākamie ieņēmumi | 2026. g. 27. jūl. |
Nākamais dividenžu datums | 2026. g. 8. jūl. |
Nākamais Ex dividenžu datums | 2026. g. 30. jūn. |
Tirgus kapitalizācija | 530M 4.3B |
|---|---|
Iepriekšējā atvēršanas cena | 37.42 |
Iepriekšējā slēgšanas cena | 36.91 |
Ziņu noskaņojums
By Acuity
100%
0%
154 / 167 Rangs Real estate
Kilroy Realty Corp Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Par Kilroy Realty Corp
Kilroy Realty Corporation (NYSE: KRC, the "Company", "Kilroy") is a leading U.S. landlord and developer, with operations in San Diego, Los Angeles, the San Francisco Bay Area, Seattle, and Austin. The Company has earned global recognition for sustainability, building operations, innovation, and design. As a pioneer and innovator in the creation of a more sustainable real estate industry, the Company's approach to modern business environments helps drive creativity and productivity for some of the world's leading technology, entertainment, life science, and business services companies. The Company is a publicly traded real estate investment trust ("REIT") and member of the S&P MidCap 400 Index with more than seven decades of experience developing, acquiring, and managing office, life science, and mixed-use projects. As of June 30, 2024, Kilroy's stabilized portfolio totaled approximately 17.0 million square feet of primarily office and life science space that was 83.7% occupied and 85.4% leased. The Company also had approximately 1,000 residential units in Hollywood and San Diego, which had a quarterly average occupancy of 92.8%. In addition, the Company had two in-process life science redevelopment projects totaling approximately 100,000 square feet with total estimated redevelopment costs of $80.0 million, and one approximately 875,000 square foot in-process development project with a total estimated investment of $1.0 billion.